Applied DNA Sciences, Inc. (NASDAQ: APDN) had its price target raised by analysts at HC Wainwright from $1.50 to $7.00. They now have a "buy" rating on the stock.
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML [Yahoo! Finance]
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
Applied DNA Sciences Second Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates [Yahoo! Finance]